Advanced renal cell carcinoma

The European Commission ( EC ) has approved Cabometyx ( Cabozantinib ) 20, 40, 60 mg for the first-line treatment...


Cabozantinib ( Cabometyx ) has shown robust clinical activity in advanced clear cell renal cell carcinoma ( RCC ). Non-clear...


The pivotal phase 3 KEYNOTE-426 trial investigating Pembrolizumab ( Keytruda ), an anti-PD-1 therapy, in combination with Axitinib ( Inlyta...


In a phase 1b trial, Avelumab ( Bavencio ) plus Axitinib ( Inlyta ) as first-line had encouraging antitumor activity...


A combination of the immune checkpoint blocker, Avelumab ( Bavencio ), plus the tyrosine kinase inhibitor ( TKI ),...


The European Commission ( EC ) has approved Fotivda ( Tivozanib ) for the treatment of adult patients with advanced...


The US Food and Drug Administration ( FDA ) has granted accelerated approval to Tecentriq ( Atezolizumab ) for the...




Results from phase 2 CABOSUN trial of Cabozantinib ( Cabometyx ) versus Sunitinib ( Sutent ) in previously untreated advanced...


Epacadostat is an oral, potent, selective inhibitor of indoleamine 2,3-dioxygenase 1 ( IDO1 ), a tryptophan-catabolizing enzyme that induces immune...


The FDA ( Food and Drug Administration ) has granted Priority Review for Atezolizumab ( anti-PD-L1; MPDL3280A ) for the...


Lenvatinib mesylate ( Lenvima ) is an orally administered multiple receptor tyrosine kinase ( RTK ) inhibitor with a novel...


The U.S. Food and Drug Administration ( FDA ) has approved an additional indication for Lenvima ( Lenvatinib mesylate )...


The FDA ( U.S. Food and Drug Administration ) has granted accelerated approval to Tecentriq ( Atezolizumab ) for the...


Renal cell carcinoma ( RCC ) accounts for approximately 330,000 cases diagnosed each year and 140,000 deaths worldwide. Most cases are...


The baseline serum cytokine levels of Platinum pretreated patients with advanced squamous non-small cell lung cancer ( NSCLC ) altered...


The FDA ( Food and Drug Administration ) has approved Cabometyx ( Cabozantinib ) for the treatment of advanced renal...


Top-line results from the CABOSUN randomized phase 2 trial of Cabozantinib ( Cabometyx; Cometriq ) in patients with previously untreated...


Final results from the randomised phase III METEOR study have confirmed the superiority of Cabozantinib over Everolimus in patients with...